Astec LifeSciences Limited has submitted a formal reply to BSE Limited in response to a surveillance query. The query, referenced under BSE's E-mail Ref. No. L/SURV/ONL/PV/SG/2026-2027/474 dated 11th November 2026, concerned a significant increase in the trading volume of the company's shares across exchanges in the recent past.
The company confirms its awareness of its responsibility to disseminate all information that could impact its share price to the stock exchanges. It states it has been promptly disclosing all events or information required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Astec LifeSciences explicitly confirms that it is in full compliance with all disclosure requirements under the Listing Regulations. Furthermore, it confirms that there are no developments, events, or information that have taken place which would require a mandatory disclosure under either the Listing Regulations or the SEBI (Prohibition of Insider Trading) Regulations, 2015.
The company assures BSE of its commitment to fully comply with its obligations and to make all appropriate disclosures as mandated by the applicable regulations when required.
The letter is signed by Tejashree Pradhan, Company Secretary & Compliance Officer (FCS 7167).